Group 1 - The company has changed its English name from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited" and its Chinese name from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司," effective from December 30, 2025 [1] - The change in company name has been approved by shareholders at a special meeting and certified by the Registrar of Companies in the Cayman Islands [1] - The new names have been registered in Hong Kong under the Companies Ordinance, confirming the new English and Chinese names [1] Group 2 - The company's stock trading name on the Hong Kong Stock Exchange will change from "GENOR" to "EDDING GENOR," and the Chinese stock name will change from "嘉和生物" to "亿腾嘉和," effective from February 6, 2026 [2] - The company's stock code on the Hong Kong Stock Exchange will remain "6998" despite the name changes [2] - The name changes aim to align with the expanded business of the group post-merger and better reflect the relationship with the controlling shareholder [2]

Core Viewpoint - The company has successfully changed its name from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited," effective from December 30, 2025, at 9:00 AM Hong Kong time [1]. Group 1 - The special resolution regarding the name change was approved at the shareholders' special meeting [1]. - The company's Chinese name has also been updated from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司" [1]. - The name change is officially recognized by the Registrar of Companies in the Cayman Islands [1].

Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received a notice of acceptance from the National Medical Products Administration for the supplemental application of intravenous immunoglobulin products [1] Group 1: Company Developments - The supplemental application for intravenous immunoglobulin in 2.5g/bottle, 5g/bottle, and 10g/bottle formats has been accepted [1] - The primary indications for intravenous immunoglobulin include primary immunoglobulin deficiency, secondary immunoglobulin deficiency diseases, and autoimmune diseases [1] Group 2: Industry Context - Current domestic companies with marketing approval for intravenous immunoglobulin (5g/bottle, 10%, 50ml) include Chengdu Rongsheng Pharmaceutical Co., Ltd., Guizhou Taibang Biologic Products Co., Ltd., and China Resources Boya Biopharmaceutical Group Co., Ltd. [1]

Core Viewpoint - The company has entered into a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Company for approximately HKD 40 million to HKD 45 million, which is seen as a strategic investment to enhance its participation in the healthcare sector and create long-term value [1] Group 1: Acquisition Details - The acquisition involves China Gene Engineering Company, which is registered in Hong Kong and holds approximately 67.68% of Shanghai Huaxin Biological High-tech Co., Ltd [1] - The total consideration for the acquisition is estimated to be between HKD 40 million and HKD 45 million [1] Group 2: Business Synergy - China Gene Group is primarily engaged in the internal research and development, manufacturing, and sales of biopharmaceutical products in China [1] - The acquisition aligns with the company's existing businesses in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services [1] Group 3: Strategic Importance - The board views the acquisition as an excellent opportunity to increase the company's involvement in the operations of China Gene Group [1] - This strategic investment is expected to generate potential long-term value and facilitate business development in the promising healthcare industry [1]

Core Viewpoint - The approval of M 701 by the FDA marks a significant advancement in the clinical development of a novel therapy for malignant pleural effusion (MPE), providing new hope for patients globally [1] Company Summary - Youzhiyou Biotechnology-B (02496) announced that its recombinant anti-epithelial cell adhesion molecule (Ep CAM) and cluster of differentiation 3 (CD3) human-mouse chimeric bispecific antibody M 701 received IND approval from the FDA on January 31, 2026 [1] - M 701 targets Ep CAM and CD3, with Ep CAM being highly expressed in epithelial-derived malignant pleural effusion tumor cells, making it a key therapeutic target [1] Industry Summary - Malignant pleural effusion is a common and severe complication of malignant tumors, particularly in advanced lung and breast cancer patients, with current treatments primarily focused on palliative care [1] - There is an urgent need for innovative strategies to fill the clinical gap in treating MPE, which M 701 aims to address through its precise targeting and immune activation [1] - The approved clinical trial is an open-label, multi-center, Phase Ib/II study designed to evaluate the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of M 701 in patients with malignant pleural effusion caused by advanced epithelial tumors [1]

Core Viewpoint - The approval of the clinical trial application for M701 by the FDA marks a significant advancement in the international clinical development of a novel therapy targeting malignant pleural effusion (MPE), offering new hope for patients globally [1] Group 1: Company Developments - Youzhiyou Biotech-B (02496) announced the FDA's approval for the clinical trial of M701, a recombinant bispecific antibody targeting EpCAM and CD3, set to begin on January 31, 2026 [1] - M701 is designed to address MPE, a common and severe complication in malignant tumors, particularly in late-stage lung and breast cancer patients, where current treatments primarily focus on palliative care [1] Group 2: Product Details - M701 specifically targets EpCAM, which is frequently expressed in epithelial-derived malignant pleural effusion tumor cells, and CD3, which activates the body's anti-tumor immunity, enabling precise treatment through their synergistic action [1] - The approved clinical trial is an open-label, multicenter, Phase Ib/II study aimed at evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of M701 in patients with malignant pleural effusion caused by advanced epithelial tumors [1]

Core Viewpoint - The company EPS Creative Technology (03860) has signed a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Co., Ltd. from Hongshida Medical Co., Ltd. for approximately HKD 40 million to HKD 45 million, which is seen as a strategic investment to enhance its involvement in the healthcare sector and create long-term value [1][1][1] Group 1 - The acquisition involves China Gene Engineering, a Hong Kong-registered company that holds about 67.68% of Shanghai Huaxin Bio-Technology Co., Ltd. [1] - The transaction is expected to complement the company's existing businesses in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services [1][1] - Upon completion, the investment in China Gene will be recognized as an investment in an associate company in the group's consolidated financial statements [1]

Core Viewpoint - The company, EPS Creation Technology (03860.HK), has signed a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Co., Ltd, which is seen as a strategic investment to enhance its involvement in the biopharmaceutical sector and create long-term value [1] Group 1: Acquisition Details - The acquisition involves China Gene Engineering Co., Ltd, a company registered in Hong Kong, which holds approximately 67.68% of Shanghai Huaxin Biological High-Tech Co., Ltd [1] - The acquisition is expected to be recognized as an investment in an associate company in the consolidated financial statements of the group upon completion [1] Group 2: Strategic Importance - The board believes that this acquisition presents an excellent opportunity for the group to expand its operational involvement with China Gene Group [1] - The investment aligns with the group's existing business in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services, thereby complementing its current operations [1]

Core Viewpoint - The approval of the clinical trial application for M701 by the FDA marks a significant advancement in the international clinical development of an innovative therapy targeting malignant pleural effusion (MPE), providing new hope for patients globally [1] Group 1: Product Development - The product M701 is a recombinant bispecific antibody targeting epithelial cell adhesion molecule (Ep CAM) and cluster of differentiation 3 (CD3), specifically designed for treating MPE [1] - M701 targets Ep CAM, which is highly expressed in tumor cells associated with epithelial-derived malignant pleural effusion, making it a critical therapeutic target [1] - The clinical trial is an open-label, multicenter, Phase Ib/II study aimed at evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of M701 in patients with malignant pleural effusion caused by advanced epithelial tumors [1] Group 2: Clinical Need - Malignant pleural effusion is a common and severe complication of malignant tumors, particularly in patients with advanced lung and breast cancers, highlighting the urgent need for innovative treatment strategies to fill the clinical gap [1] - Current treatment approaches primarily focus on palliative care, indicating a significant opportunity for new therapeutic options in this area [1]

香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）謹此向本公司股東（「股東」）及本公司潛在投資者提供 更新資料，經進一步策略性考量後，本集團正考慮收購目標公司的間接少數權益，而非 先前該公告所披露的控股權。 於二零二六年二月三日，本公司（作為買方）與鴻事達醫療有限公司（「賣方」）（作為賣方） 就建議收購中國基因工程有限公司（「中國基因」）16.23%股權（「建議收購事項」）訂立諒解 備忘錄（「諒解備忘錄」）。中國基因為一間於香港註冊成立的公司，實益擁有上海華新生 物高技術有限公司（「華新」）約67.68%股權。華新為一間於中華人民共和國（「中國」）註冊 成立的公司，連同中國基因及其附屬公司統稱「中國基因集團」。 訂約方協定將以真誠原則進行磋商，確保儘快就建議收購事項訂立正式協議（「正式協 議」），惟無論如何不得遲於二零二六年三月六日或訂約方或會協定的任何較後日期。除 包括獨家及保密等對訂約方具有約束力的若干條款 ...